AZN logo

AZNAstraZeneca PLC

$182.28
$3.32
(1.85%)
Today
Closed $182.28
$0.00
(0.00%)
After Hours
Updated: 04:15 PM EDT
Reported EarningsApr 29
Mkt Cap$277.54B
Vol1.67M
60

Bullish Sentiment

How do you feel about AZN?

News
all
press releases
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Zacks
News Placeholder
More News
News Placeholder
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
News Placeholder
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
News Placeholder
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
News Placeholder
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
News Placeholder
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
News Placeholder
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
News Placeholder
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
News Placeholder
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
News Placeholder
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
<
1
2
...
>

Advertisement|Remove ads.